Clinical Report: RA Outcomes Improved in KURAMA Cohort
Overview
In a 10-year study of patients with rheumatoid arthritis, improvements in disease activity and functional disability were observed, correlating with increased use of biologic and targeted synthetic DMARDs and reduced glucocorticoid use. The study analyzed data from the Kyoto University Rheumatoid Arthritis Management Alliance cohort from 2012 to 2021.
Background
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that can lead to joint damage and disability. Effective management of RA is crucial for improving patient outcomes and quality of life. The increasing use of biologic and targeted synthetic DMARDs has been noted in treatment strategies.
Data Highlights
| Year | Biologic/tsDMARD Use (%) | Glucocorticoid Use (%) | DAS28-CRP Remission (%) | CDAI Remission (%) | HAQ-DI Score |
|---|---|---|---|---|---|
| 2012 | 30 | 41 | - | 25 | 0.69 |
| 2021 | 53 | 19 | 80 | 48 | 0.25 |
Key Findings
- Biologic or targeted synthetic DMARD use increased from 30% to 53% over the study period.
- Glucocorticoid use decreased from 41% to 19%.
- Disease Activity Score 28-C-reactive protein remission reached 80% in 2021.
- Clinical Disease Activity Index remission improved from 25% to 48%.
- Median Health Assessment Questionnaire Disability Index scores decreased from 0.69 to 0.25.
- Interleukin-6 receptor inhibitors showed improvement in some measures compared to abatacept.
Clinical Implications
The findings suggest that the increased use of biologic and targeted synthetic DMARDs may contribute to improved disease management in RA patients. Clinicians should consider these treatment modalities to enhance patient outcomes, particularly in light of the observed reductions in glucocorticoid use.
Conclusion
The KURAMA cohort study reports improvements in RA management over a decade, with changes in disease activity and functional outcomes linked to treatment strategies.
Related Resources & Content
- Fujii T., Kyoto University Graduate School of Medicine, 2023 -- RA Outcomes Improved in KURAMA Cohort
- Effects of a kidney-specific ERAS® protocol on postoperative results in patients receiving partial nephrectomy
- Knee Surgery, Sports Traumatology, Arthroscopy — Outcomes After Primary Knee Arthroplasty Are Comparable in Hospitals with Varying Revision Rates: One-Year Follow-Up from the Danish Multicenter Cohort Study, SPARK
- Knee Surgery, Sports Traumatology, Arthroscopy — Long-term Patient-Reported Outcomes After Total and Minimally Invasive Unicompartmental Knee Arthroplasty: A Propensity Score-Matched Analysis Over Ten Years
- European Journal of Preventive Cardiology — Effects of inpatient and outpatient cardiac rehabilitation on the 5-year prognosis in patients with acute myocardial infarction
- Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs
- EULAR’s 2025 update on RA management
- Three-Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
